Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Glaucoma
Interventions
DRUG

AR-12286 0.5% ophthalmic solution

q.d. PM

DRUG

AR-12286 0.25% Ophthalmic solution

q.d. PM

DRUG

Latanoprost ophthalmic solution

q.d. PM

Trial Locations (18)

10029

Mount Sinai School Of Medicine, New York

12159

Glaucoma Consultants of the Capital Region, Slingerlands

14618

Rochester Ophthalmology Group, Rochester

28210

Charlotte Eye Ear Nose and Throat, Charlotte

30076

Coastal Research Associates, LLC, Roswell

33321

Marvin Greenberg, MD, Tamarac

34994

East Florida Eye Institute, Stuart

37803

Univ Eye Surgeons, Maryville Ctr., Maryville

40217

Taustine Eye Center, Louisville

57701

Black Hills Regional Eye Institute, Rapid City

63090

Comprehensive Eye Care, St Louis

66204

Bradley Kwapiszeski, MD, Shawnee Mission

74104

The Eye Institute, Tulsa

78731

Texan Eye, Austin

Medical Center Ophth. Associates, San Antonio

90301

United Medical Research Institute, Inglewood

92064

Centre For Health Care, Poway

94954

North Bay Eye Associates, Petaluma

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT01060579 - Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure | Biotech Hunter | Biotech Hunter